AX-2025-020262 · Enclomiphene citrate · GGPeps lot GGPE-2410-S2226

Section 1

Results

Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	98.12	% area	≥ 98.5	FAIL
Total impurities	RP-HPLC, sum of reported peaks	1.88	% area	≤ 1.5	FAIL
Largest single impurity	RP-HPLC — zuclomiphene (cis-isomer)	1.25	% area	≤ 1.00	FAIL
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	62.58	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	61.40	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	19.56	mg	12.5 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	12.010	mg	12.5 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	96.1	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	4.27	%	≤ 10.0	PASS
Counter-ion (citrate)	anion-exchange ion chromatography	32.86	%	≤ 12.0	FAIL
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.29	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.51	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.32	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	14.02	min	13.92 ± 0.35 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.12	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	75,949	—	≥ 20,000	PASS
Resolution to nearest impurity	vs free base (des-citrate)	0.08	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 75,949, and skew follows the reported asymmetry factor of 1.12. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.25 % impurity against a 98.12 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Enclomiphene citrate — main peak	14.02	4,768,936	98.12	—
2	zuclomiphene (cis-isomer)	13.50	60,754	1.25	0.000
3	free base (des-citrate)	14.04	18,469	0.38	-192.027
4	N-oxide (+16 Da)	13.29	8,263	0.17	+15.995
5	des-ethyl enclomiphene (−28 Da)	13.65	3,888	0.08	-28.031
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.27
Counter-ion (citrate)	ion chromatography	32.86
Residual solvent + inorganic residue	estimated	0.29
Total peptide content	by difference	62.58
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.60	98.12	divergence +0.33 pp vs batch median
Total impurities (% area)	1.40	1.88
Largest single impurity (% area)	0.87	1.25
Water (%)	3.0	4.27
Counter-ion (%)	7.3	32.86
Peptide content (%w/w)	89.1	62.58
Endotoxin (EU/mg)	not stated	0.51
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (2–8 °C, 23 d) → laboratory (courier, ambient, 2 d) → assay.
Assay date: 17 Feb 2025
Submitted to the index: 27 Feb 2025
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: PARTIAL

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

uncertainty_budget27 Feb 2025

The gap between 98.12 % and the class specification should be read against an expanded uncertainty of roughly ±0.5 pp. A shortfall inside that band is not a finding; a shortfall well outside it is.

prep_hplc_cut27 Feb 2025

The record is published in full, including the impurity table that explains it. A number below specification with a named impurity profile beside it is more useful than a number above specification with nothing beside it.

label_claim27 Feb 2025

A retail vial is also a test of the label. Declared claim 12.5 mg against what the gravimetry recovers is a question only a purchased vial can answer honestly.

Section 7

Related records

Same batch — lot GGPE-2410-S2226 n=13

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-020252	GGPE-2410-S2226	Janoshik	2025-Q1	98.09	3.88	95.3	Laboratory-retained	0	FAIL
AX-2025-020253	GGPE-2410-S2226	Nordanalyt	2025-Q1	98.84	3.91	107.1	Supplier-supplied	0	FAIL
AX-2025-020254	GGPE-2410-S2226	Medutest	2025-Q1	98.47	3.35	—	Buyer-sourced	1	FAIL
AX-2025-020255	GGPE-2410-S2226	PeptideMeter	2025-Q1	98.30	4.05	90.6	Buyer-sourced	0	FAIL
AX-2025-020256	GGPE-2410-S2226	Nordanalyt	2025-Q1	98.35	4.16	89.7	Buyer-sourced	1	FAIL
AX-2025-020257	GGPE-2410-S2226	Medutest	2025-Q1	98.03	3.71	—	Buyer-sourced	0	FAIL
AX-2025-020258	GGPE-2410-S2226	Janoshik	2025-Q1	98.44	3.76	97.1	Buyer-sourced	0	FAIL
AX-2025-020259	GGPE-2410-S2226	Medutest	2025-Q1	98.94	4.02	98.6	Supplier-supplied	0	FAIL
AX-2025-020260	GGPE-2410-S2226	Janoshik	2025-Q1	98.27	3.70	—	Buyer-sourced	0	FAIL
AX-2025-020261	GGPE-2410-S2226	VendorInvestigate	2025-Q1	97.74	3.73	—	Buyer-sourced	0	FAIL
AX-2025-020263	GGPE-2410-S2226	Janoshik	2025-Q1	98.12	3.85	101.5	Buyer-sourced	0	FAIL
AX-2025-020264	GGPE-2410-S2226	Janoshik	2025-Q1	98.27	3.99	94.6	Buyer-sourced	0	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Enclomiphene citrate records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041525	QSC	QSC-2604-R6644	PeptideMeter	2026-Q2	99.80	4.04	101.5	Laboratory-retained	0	FAIL
AX-2026-042329	TFC	TFC-2605-H2745	Nordanalyt	2026-Q2	99.41	3.67	—	Buyer-sourced	2	FAIL
AX-2026-041524	QSC	QSC-2604-R6644	PeptideMeter	2026-Q2	99.93	4.60	91.6	Buyer-sourced	0	FAIL
AX-2026-041526	QSC	QSC-2604-R6644	Medutest	2026-Q2	99.68	4.25	103.7	Buyer-sourced	1	FAIL
AX-2026-043164	SSA	SSA-2603-C7061	Kestrel	2026-Q2	98.48	3.27	107.4	Buyer-sourced	2	FAIL
AX-2026-041773	ASY	ASY-{CAT}-1806	Janoshik	2025-Q4	99.88	3.59	—	Buyer-sourced	1	FAIL
AX-2025-019360	HYB	HYB-2510-J6404	Medutest	2025-Q4	99.61	5.07	98.1	Laboratory-retained	0	FAIL
AX-2025-018986	ASY	ASY-{CAT}-1806	Medutest	2025-Q4	99.93	3.35	—	Buyer-sourced	1	FAIL

Other recent GGPeps records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042784	CJC-1295 (no DAC)	GGPE-2606-E1234	Medutest	2026-Q3	98.27	4.55	—	Buyer-sourced	PASS
AX-2026-042786	CJC-1295 (no DAC)	GGPE-2606-E1234	Janoshik	2026-Q3	98.22	3.77	—	Buyer-sourced	PASS
AX-2026-042858	Selank	GGPE-2603-J2447	VendorInvestigate	2026-Q3	98.87	8.85	99.4	Buyer-sourced	FAIL
AX-2026-042783	CJC-1295 (no DAC)	GGPE-2606-E1234	Janoshik	2026-Q3	98.22	4.45	90.6	Buyer-sourced	PASS
AX-2026-042757	Melanotan II	GGPE-2603-P1474	Janoshik	2026-Q3	99.54	6.78	92.0	Buyer-sourced	PASS
AX-2026-042785	CJC-1295 (no DAC)	GGPE-2606-E1234	PeptideMeter	2026-Q3	97.70	4.64	91.4	Buyer-sourced	FAIL
AX-2026-042756	Melanotan II	GGPE-2603-P1474	Nordanalyt	2026-Q3	99.17	7.04	—	Buyer-sourced	PASS
AX-2026-042755	Melanotan II	GGPE-2603-P1474	Nordanalyt	2026-Q3	99.25	6.58	90.4	Buyer-sourced	PASS